Zydus Lifesciences' Desidustat Approved by China for Renal Anaemia Treatment

Zydus Lifesciences has received approval from China's National Medical Products Administration (NMPA) for its oral drug Desidustat, used to treat renal anaemia in Chronic Kidney Disease (CKD) patients. The company licensed the drug to a subsidiary of China Medical System Holdings Ltd in 2020. Desidustat, marketed in India as Oxemia, has treated over 100,000 CKD patients since 2022. With over 120 million CKD patients in China, Zydus aims to expand access across Greater China.